Stella Capital Announces investment in Schain Research and Mailo Global
Stockholm, 2023-07-11 - Stella Capital, a growth equity firm focused on Nordic technology, SaaS and e-commerce companies, is pleased to announce its minority stake investment in Schain Research and Mailo Global, two prominent companies in the healthcare research and software-as-a-service (SaaS) sectors, respectively. The investment marks Stella’s entry within the healthcare sector, demonstrating the firm’s commitment to supporting innovative ventures in key industries.
Schain Research, a renowned data-driven consultancy company specializing in health outcomes studies for drug development, brings a wealth of expertise to the table. Leveraging the Nordic region's reliable healthcare and medical registries, Schain Research conducts comprehensive studies that enable groundbreaking health outcomes research for its clients. The company is at the forefront of Real-world Evidence (RWE), a rapidly growing market with immense potential.
Mailo Global, a SaaS company offering its software; Real-world Evidence Explorer (RWEX), addresses a critical need for reliable and robust analyses in the drug development process. By providing access to anonymized population-based longitudinal data, Mailo Global empowers clients to make informed decisions throughout the drug development lifecycle. Stella Capital's investment in Mailo Global underscores its commitment to supporting cutting-edge technologies and solutions that enable evidence-based decision-making in the healthcare sector.
Anders Brenner, Founder and Partner at Stella Capital, expressed his enthusiasm, stating: "We are thrilled to partner with founder Frida Schain and her team. Both Schain Research and Mailo Global possess exceptional expertise and align perfectly with our investment strategy. These companies lay the foundation for building domain knowledge within the healthcare sector and provide deep insights into its digitalization. Through our active ownership approach, we will support their growth and innovation."
Schain Research and Mailo Global will continue operating as independent entities, maintaining their existing management teams. This structure ensures that both companies can continue their successful operations while benefiting from Stella Capital's strategic guidance and resources.
"We are excited about the partnership with Stella Capital and the growth opportunities it presents," commented Frida Schain founder of Schain Research and co-founder of Mailo Global. "Joining forces with Stella Capital will accelerate our expansion plans, enhance our capabilities, and allow us to deliver even greater value to our clients. Together, we will drive innovation and advance the frontiers of healthcare research and technology."
Stella Capital's investment in Schain Research and Mailo Global marks another milestone in the company's mission to invest in high-potential companies and contribute to their success. With a strong track record of supporting growth-oriented companies, Stella Capital remains committed to fostering innovation, driving value creation, and making a positive impact in the industries it operates.
For media inquiries or further information, please contact:
Anders Brenner
Founding Partner Stella Capital
Anders.brenner@stellacapital.se
+46 70 265 01 32
About Stella Capital
Stella Capital is a leading growth equity firm based in Stockholm, specializing in Nordic technology, SaaS, and e-commerce companies. With a focus on technology-driven growth companies, Stella Capital takes an active ownership role to support companies in achieving their full potential By providing strategic guidance, capital resources, and industry expertise, Stella Capital enables its portfolio companies to thrive in dynamic markets.
For more information about Stella Capital, please visit www.Stellacapital.se
About Schain Research
Schain Research is a consultancy company specialized in conducting health outcomes studies to support drug development. Leveraging Sweden's comprehensive healthcare system and advanced registry linkage capabilities, Schain Research delivers unique and insightful research findings to its clients. With a network of academic experts and interdisciplinary partners, Schain Research provides end-to-end support for health outcomes studies across various therapeutic areas.
For more information about Schain Research, please visit www.schainresearch.com
About Mailo Global
Mailo Global was established in 2022 and provides instant access to anonymized longitudinal population-based patient level data to answer your epidemiological key questions. Customers can access and visualize the data in the interactive tool RWEX. The team has long experience in software development, machine learning and evidence generation throughout clinical development programs. Mailo are passionate to improve lives of patients by using robust data for better decision making in healthcare.
For more information about Mailo Global, please visit www.mailo.global
